AMRX
Amneal Pharmaceuticals, Inc.
Key Financials
Gross Profit
$1.1B
↑ 9.1%
Operating Income
$394.1M
↑ 58.1%
Revenue
$3.0B
↑ 8.0%
Total Assets
$3.7B
↑ 5.1%
Net Income
$72.1M
↑ 161.6%
EPS (Diluted)
$0.22
↑ 157.9%
Cash & Equivalents
$282.0M
↑ 155.1%
Total Liabilities
$0.00
N/A
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 9/21/2026 | View on SEC |
| 4 | 9/14/2026 | View on SEC |
| S-3ASR | 9/3/2026 | View on SEC |
| 4 | 9/2/2026 | View on SEC |
| 4 | 8/25/2026 | View on SEC |
| 4 | 8/14/2026 | View on SEC |
| 4 | 8/13/2026 | View on SEC |
| 4 | 8/13/2026 | View on SEC |
| 4 | 8/13/2026 | View on SEC |
| 144 | 8/13/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | AMRX |
| Company Name | Amneal Pharmaceuticals, Inc. |
| CIK | 1723128 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| Phone | (908) 947-3120 |